// App-Quantinova.ai

ABS128 : IMPROVEMENT IN PAIN‐RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA A TREATED WITH RFVIIIFC INDIVIDUALIZED PROPHYLAXIS: POST‐HOC ANALYSIS FROM A‐LONG

Researchers

Presenter

  • J. Pasi

Principal Investigators

  • C. Hermans

  • Z. Hakimi

  • J. Nazir

  • P. DasMahapatra

  • S. Aballa

  • M. Ezzalfani

  • F. A. Fatoye

Medical Centers

  • Haemophilia Centre, Royal London Hospital Barts and The London School of Medicine, London, United Kingdom

  • Division of Hematology, Hemostasis and Thrombosis Unit, Saint‐Luc University Hospital, Brussels, Belgium

  • Swedish Orphan Biovitrum AB, Stockholm, Sweden

  • Sanofi, Cambridge, United States

  • Creativ‐Ceutical, Rotterdam, Netherlands

  • Creativ-Ceutical, Paris, France

  • Department of Health Professions, Faculty of Health, Manchester Metropolitan University, Manchester, United Kingdom

Locations

  • United Kingdom

  • Belgium

  • Sweden

  • United States

  • Netherlands

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIIIFc

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01181128

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved